Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
This is a multicenter, multi-arm, international, phase Ib, 3 x 3 dose-escalation study with an initial phase I followed by an expansion phase. The primary objective of the phase Ib is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and dose limiting toxicity (DLT) of various combinations of pembrolizumab, pralatrexate and decitabine.
Novel immuno-epigenetic based platform for patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): an international phase Ib study of pembrolizumab combined with decitabine and/or pralatrexate
- ClinicalTrials.gov Identifier: NCT03240211
- Protocol Number: 18-363
- Principal Investigator: Salvia Jain
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required